Based on the key indicators related to Milestone Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Milestone Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Milestone Pharmaceuticals' Other Stockholder Equity is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 102.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 63.9 M in 2024. Key indicators impacting Milestone Pharmaceuticals' financial strength include:
The financial analysis of Milestone Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Milestone Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(62.67 Million)
Milestone
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Other Non Cash Items
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Retained Earnings Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Capital Stock
Short Long Term Debt Total
Capital Lease Obligations
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Milestone Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Milestone Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Milestone Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Milestone Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Milestone Pharmaceuticals. Check Milestone Pharmaceuticals' Beneish M Score to see the likelihood of Milestone Pharmaceuticals' management manipulating its earnings.
Milestone Pharmaceuticals Stock Summary
Milestone Pharmaceuticals competes with DiaMedica Therapeutics, Seres Therapeutics, Inhibikase Therapeutics, Oncolytics Biotech, and Scpharmaceuticals. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Milestone Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Milestone Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Milestone Pharmaceuticals competition to find correlations between indicators driving Milestone Pharmaceuticals's intrinsic value. More Info.
Milestone Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Milestone Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Milestone Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Milestone Pharmaceuticals Systematic Risk
Milestone Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Milestone Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Milestone Pharmaceuticals correlated with the market. If Beta is less than 0 Milestone Pharmaceuticals generally moves in the opposite direction as compared to the market. If Milestone Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Milestone Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Milestone Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Milestone Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Milestone Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Milestone Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Milestone Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.39)
At this time, Milestone Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Milestone Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Milestone Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Milestone Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Milestone Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Milestone Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Milestone Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.